Home > Press Releases > AI-based Drug Repurposing Market

AI-based Drug Repurposing Market Likely to Surpass USD 2.2 Billion by 2035

Report Code: HC-11173 | Published in: Jul 2026, By MarketGenics | Number of pages: 320

Global AI-based Drug Repurposing Market Forecast 2035:

According to the report, the global AI-based drug repurposing market is projected to expand from USD 0.3 billion in 2025 to USD 2.2 billion by 2035, registering a CAGR of 23.1%, the highest during the forecast period. The AI-based drug repurposing market is growing as pharmaceutical companies invest more in AI-driven drug discovery, and multimodal biological data analytics are becoming more popular and strategic business partnerships are emerging between AI technology providers and biopharmaceutical companies.

Chronic diseases are on the rise and the need for quicker, cheaper drug development is driving market growth. For instance, in March 2026, Insilico Medicine entered into a strategic partnership with Eli Lilly worth up to $2.75 billion, utilizing its Pharma. platform.AI system to identify and develop several therapeutics.

Moreover, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the biopharmaceutical sector spends over US$200 billion each year on research and development, driving the further adoption of AI in drug discovery and repurposing processes. The commercialization and adoption of AI drug repurposing solutions are gaining momentum globally, driven by increasing investments in AI and growing pharmaceutical partnerships.

Key Driver, Restraint, and Growth Opportunity Shaping the Global AI-based Drug Repurposing Market

The growing availability of genomic databases, electronic health records (EHRs), real-world evidence (RWE), and multiomics datasets is enhancing the performance of AI-based drug repurposing platforms. The availability of high-quality biological and clinical data helps AI systems detect new potential drug–disease connections, refine predictions of drug efficacy, and speed up the drug repurposing process in various therapeutic fields.

Intellectual property limits continue to be a major hurdle for the AI-based drug repurposing market, especially for off-patent pharmaceuticals with limited market exclusivity. Reduced patent protection and pricing pressures can reduce commercial profits, limiting investment in repurposed initiatives with strong clinical potential.

The increasing focus on rare and orphan diseases presents a significant opportunity for AI-based drug repurposing. The ability to rapidly identify existing compounds for rare diseases using AI can cut development times and costs, and increased regulatory support and precision medicine advances are driving commercial use across underrepresented therapeutic areas.

Expansion of the Global AI-based Drug Repurposing Market

Expansion of AI-powered Precision Medicine and Biomarker-Driven Drug Repurposing

The growth of precision medicine and the repurposing of drugs based on biomarkers is driving market growth, by identifying novel therapeutic windows for existing drugs and new indications for these drugs in individual patients. The combination of genomic, molecular, and clinical data facilitates more precise target selection, better treatment efficacy, and more efficient AI-driven drug discovery and repurposing efforts.
For instance, in March 2026, Tempus AI entered into a multi-year partnership with Merck & Co. to advance AI for precision medicine biomarker discovery through its Lens platform and multimodal datasets for oncology drug development and precision therapeutics.
This is driving the use of AI in precision medicine, increasing the likelihood of successful drug repurposing and enhancing commercialization opportunities in the pharmaceutical sector of R&D.

Regional Analysis of Global AI-based Drug Repurposing Market

North America accounts for the highest demand in the global AI-based drug repurposing market as it has a well-developed AI research ecosystem, strong pharmaceutical and biotechnology industry presence, large biomedical datasets, and high investment in computational drug discovery. The region also has cutting-edge cloud infrastructure, a strong precision medicine adoption, and a great innovation ecosystem that further drives the speed of therapeutic development and commercialization using AI technologies. North America's market dominance is further bolstered by strong AI capabilities and investments in pharmaceuticals.
Asia Pacific is experiencing a high rate of growth, as the government is investing heavily in AI, expanding pharmaceutical research and development initiatives, rising adoption of precision medicine, and investments in digital healthcare infrastructure are driving the market. The growing biotechnology landscape and healthcare data in the region are driving the development and commercialization of AI-based drug repurposing.

Prominent players operating in the global AI-based drug repurposing market is BenevolentAI Limited, BioXcel Therapeutics Inc, BullFrog AI Holdings, Inc., Healx Limited, Insilico Medicine, Inc., Lantern Pharma Inc., Recursion Pharmaceuticals, Inc., Other Key Players.

The global AI-based drug repurposing market has been segmented as follows:

Global AI-based Drug Repurposing Market Analysis, By Component

Software
- AI Drug Discovery Platforms
- Drug Repurposing Software
- Predictive Analytics Software
- Molecular Modeling & Simulation Software
- Bioinformatics Software
- Clinical Data Analytics Software
- Workflow Management Software
- Cloud-Based Drug Discovery Platforms
- Others
Hardware
- High-Performance Computing (HPC) Systems
- AI Servers & Workstations
- GPU Computing Infrastructure
- Data Storage Systems
- Networking & Connectivity Equipment
- Security Infrastructure
- Others
Services
- Consulting Services
- System Integration & Deployment Services
- AI Model Development & Customization
- Bioinformatics & Data Analysis Services
- Cloud & Managed Services
- Technical Support & Maintenance
- Training & Education Services
- Regulatory & Compliance Services
- Others

Global AI-based Drug Repurposing Market Analysis, By Deployment Mode

Cloud-Based
On-Premises
Hybrid

Global AI-based Drug Repurposing Market Analysis, By Technology

Machine Learning (ML)
Deep Learning
Natural Language Processing (NLP)
Generative AI
Knowledge Graph-Based AI
Predictive Analytics
Computer Vision
Reinforcement Learning
Others

Global AI-based Drug Repurposing Market Analysis, By Drug Type

Small Molecules
Biologics
Biosimilars
Peptides
Vaccines
Cell & Gene Therapy Candidates
RNA-Based Therapeutics
Combination Therapies
Others

Global AI-based Drug Repurposing Market Analysis, By Workflow

Target Identification
Drug Candidate Screening
Drug Repurposing Prediction
Molecular Modeling & Simulation
Biomarker Discovery
Clinical Trial Optimization
Safety & Toxicity Assessment
Regulatory Data Analysis
Others

Global AI-based Drug Repurposing Market Analysis, By Therapeutic Stage

Preclinical Research
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Post-Marketing Studies

Global AI-based Drug Repurposing Market Analysis, By Application

Oncology
Neurology
Infectious Diseases
Rare Diseases
Cardiovascular Diseases
Metabolic Disorders
Immunology & Autoimmune Diseases
Respiratory Diseases
Gastrointestinal Diseases
Dermatology
Others

Global AI-based Drug Repurposing Market Analysis, By End User

Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Hospitals
Government Research Organizations
Clinical Research Organizations
Drug Discovery Startups
Others

Global AI-based Drug Repurposing Market Analysis, By Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global AI-based Drug Repurposing Market Outlook
  - 2.1.1. AI-based Drug Repurposing Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2026-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.4. Trump Tariff Impact Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Increasing adoption of AI-powered drug discovery and computational biology platforms
    - 4.1.1.2. Growing availability of genomic, multiomics, and real-world healthcare datasets
    - 4.1.1.3. Expansion of AI-powered precision medicine and biomarker-driven drug repurposing
  - 4.1.2. Restraints
    - 4.1.2.1. Intellectual property and limited market exclusivity for repurposed drugs
    - 4.1.2.2. Limited availability of standardized, high-quality biomedical data for AI model training
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Eco-system Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global AI-based Drug Repurposing Market Demand
  - 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global AI-based Drug Repurposing Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
  - 6.2.1. Software
    - 6.2.1.1. AI Drug Discovery Platforms
    - 6.2.1.2. Drug Repurposing Software
    - 6.2.1.3. Predictive Analytics Software
    - 6.2.1.4. Molecular Modeling & Simulation Software
    - 6.2.1.5. Bioinformatics Software
    - 6.2.1.6. Clinical Data Analytics Software
    - 6.2.1.7. Workflow Management Software
    - 6.2.1.8. Cloud-Based Drug Discovery Platforms
    - 6.2.1.9. Others
  - 6.2.2. Hardware
    - 6.2.2.1. High-Performance Computing (HPC) Systems
    - 6.2.2.2. AI Servers & Workstations
    - 6.2.2.3. GPU Computing Infrastructure
    - 6.2.2.4. Data Storage Systems
    - 6.2.2.5. Networking & Connectivity Equipment
    - 6.2.2.6. Security Infrastructure
    - 6.2.2.7. Others
  - 6.2.3. Services
    - 6.2.3.1. Consulting Services
    - 6.2.3.2. System Integration & Deployment Services
    - 6.2.3.3. AI Model Development & Customization
    - 6.2.3.4. Bioinformatics & Data Analysis Services
    - 6.2.3.5. Cloud & Managed Services
    - 6.2.3.6. Technical Support & Maintenance
    - 6.2.3.7. Training & Education Services
    - 6.2.3.8. Regulatory & Compliance Services
    - 6.2.3.9. Others
7. Global AI-based Drug Repurposing Market Analysis, by Deployment Mode
- 7.1. Key Segment Analysis
- 7.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
  - 7.2.1. Cloud-Based
  - 7.2.2. On-Premises
  - 7.2.3. Hybrid
8. Global AI-based Drug Repurposing Market Analysis, by Technology
- 8.1. Key Segment Analysis
- 8.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
  - 8.2.1. Machine Learning (ML)
  - 8.2.2. Deep Learning
  - 8.2.3. Natural Language Processing (NLP)
  - 8.2.4. Generative AI
  - 8.2.5. Knowledge Graph-Based AI
  - 8.2.6. Predictive Analytics
  - 8.2.7. Computer Vision
  - 8.2.8. Reinforcement Learning
  - 8.2.9. Others
9. Global AI-based Drug Repurposing Market Analysis, by Drug Type
- 9.1. Key Segment Analysis
- 9.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Drug Type, 2021-2035
  - 9.2.1. Small Molecules
  - 9.2.2. Biologics
  - 9.2.3. Biosimilars
  - 9.2.4. Peptides
  - 9.2.5. Vaccines
  - 9.2.6. Cell & Gene Therapy Candidates
  - 9.2.7. RNA-Based Therapeutics
  - 9.2.8. Combination Therapies
  - 9.2.9. Others
10. Global AI-based Drug Repurposing Market Analysis, by Workflow
- 10.1. Key Segment Analysis
- 10.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Workflow, 2021-2035
  - 10.2.1. Target Identification
  - 10.2.2. Drug Candidate Screening
  - 10.2.3. Drug Repurposing Prediction
  - 10.2.4. Molecular Modeling & Simulation
  - 10.2.5. Biomarker Discovery
  - 10.2.6. Clinical Trial Optimization
  - 10.2.7. Safety & Toxicity Assessment
  - 10.2.8. Regulatory Data Analysis
  - 10.2.9. Others
11. Global AI-based Drug Repurposing Market Analysis, by Therapeutic Stage
- 11.1. Key Segment Analysis
- 11.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Therapeutic Stage Technology, 2021-2035
  - 11.2.1. Preclinical Research
  - 11.2.2. Phase I Clinical Trials
  - 11.2.3. Phase II Clinical Trials
  - 11.2.4. Phase III Clinical Trials
  - 11.2.5. Post-Marketing Studies
12. Global AI-based Drug Repurposing Market Analysis, by Application
- 12.1. Key Segment Analysis
- 12.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
  - 12.2.1. Oncology
  - 12.2.2. Neurology
  - 12.2.3. Infectious Diseases
  - 12.2.4. Rare Diseases
  - 12.2.5. Cardiovascular Diseases
  - 12.2.6. Metabolic Disorders
  - 12.2.7. Immunology & Autoimmune Diseases
  - 12.2.8. Respiratory Diseases
  - 12.2.9. Gastrointestinal Diseases
  - 12.2.10. Dermatology
  - 12.2.11. Others
13. Global AI-based Drug Repurposing Market Analysis, by End User
- 13.1. Key Segment Analysis
- 13.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
  - 13.2.1. Pharmaceutical Companies
  - 13.2.2. Biotechnology Companies
  - 13.2.3. Contract Research Organizations (CROs)
  - 13.2.4. Academic & Research Institutes
  - 13.2.5. Hospitals
  - 13.2.6. Government Research Organizations
  - 13.2.7. Clinical Research Organizations
  - 13.2.8. Drug Discovery Startups
  - 13.2.9. Others
14. Global AI-based Drug Repurposing Market Analysis, by Region
- 14.1. Key Findings
- 14.2. AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 14.2.1. North America
  - 14.2.2. Europe
  - 14.2.3. Asia Pacific
  - 14.2.4. Middle East
  - 14.2.5. Africa
  - 14.2.6. South America
15. North America AI-based Drug Repurposing Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. North America AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Component
  - 15.3.2. Deployment Mode
  - 15.3.3. Technology
  - 15.3.4. Drug Type
  - 15.3.5. Workflow
  - 15.3.6. Therapeutic Stage
  - 15.3.7. Application
  - 15.3.8. End User
  - 15.3.9. Country
    - 15.3.9.1. USA
    - 15.3.9.2. Canada
    - 15.3.9.3. Mexico
- 15.4. USA AI-based Drug Repurposing Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Component
  - 15.4.3. Deployment Mode
  - 15.4.4. Technology
  - 15.4.5. Drug Type
  - 15.4.6. Workflow
  - 15.4.7. Therapeutic Stage
  - 15.4.8. Application
  - 15.4.9. End User
- 15.5. Canada AI-based Drug Repurposing Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Component
  - 15.5.3. Deployment Mode
  - 15.5.4. Technology
  - 15.5.5. Drug Type
  - 15.5.6. Workflow
  - 15.5.7. Therapeutic Stage
  - 15.5.8. Application
  - 15.5.9. End User
- 15.6. Mexico AI-based Drug Repurposing Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Component
  - 15.6.3. Deployment Mode
  - 15.6.4. Technology
  - 15.6.5. Drug Type
  - 15.6.6. Workflow
  - 15.6.7. Therapeutic Stage
  - 15.6.8. Application
  - 15.6.9. End User
16. Europe AI-based Drug Repurposing Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Europe AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Component
  - 16.3.2. Deployment Mode
  - 16.3.3. Technology
  - 16.3.4. Drug Type
  - 16.3.5. Workflow
  - 16.3.6. Therapeutic Stage
  - 16.3.7. Application
  - 16.3.8. End User
  - 16.3.9. Country
    - 16.3.9.1. Germany
    - 16.3.9.2. United Kingdom
    - 16.3.9.3. France
    - 16.3.9.4. Italy
    - 16.3.9.5. Spain
    - 16.3.9.6. Netherlands
    - 16.3.9.7. Nordic Countries
    - 16.3.9.8. Poland
    - 16.3.9.9. Russia & CIS
    - 16.3.9.10. Rest of Europe
- 16.4. Germany AI-based Drug Repurposing Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Component
  - 16.4.3. Deployment Mode
  - 16.4.4. Technology
  - 16.4.5. Drug Type
  - 16.4.6. Workflow
  - 16.4.7. Therapeutic Stage
  - 16.4.8. Application
  - 16.4.9. End User
- 16.5. United Kingdom AI-based Drug Repurposing Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Component
  - 16.5.3. Deployment Mode
  - 16.5.4. Technology
  - 16.5.5. Drug Type
  - 16.5.6. Workflow
  - 16.5.7. Therapeutic Stage
  - 16.5.8. Application
  - 16.5.9. End User
- 16.6. France AI-based Drug Repurposing Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Component
  - 16.6.3. Deployment Mode
  - 16.6.4. Technology
  - 16.6.5. Drug Type
  - 16.6.6. Workflow
  - 16.6.7. Therapeutic Stage
  - 16.6.8. Application
  - 16.6.9. End User
- 16.7. Italy AI-based Drug Repurposing Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Component
  - 16.7.3. Deployment Mode
  - 16.7.4. Technology
  - 16.7.5. Drug Type
  - 16.7.6. Workflow
  - 16.7.7. Therapeutic Stage
  - 16.7.8. Application
  - 16.7.9. End User
- 16.8. Spain AI-based Drug Repurposing Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Component
  - 16.8.3. Deployment Mode
  - 16.8.4. Technology
  - 16.8.5. Drug Type
  - 16.8.6. Workflow
  - 16.8.7. Therapeutic Stage
  - 16.8.8. Application
  - 16.8.9. End User
- 16.9. Netherlands AI-based Drug Repurposing Market
  - 16.9.1. Country Segmental Analysis
  - 16.9.2. Component
  - 16.9.3. Deployment Mode
  - 16.9.4. Technology
  - 16.9.5. Drug Type
  - 16.9.6. Workflow
  - 16.9.7. Therapeutic Stage
  - 16.9.8. Application
  - 16.9.9. End User
- 16.10. Nordic Countries AI-based Drug Repurposing Market
  - 16.10.1. Country Segmental Analysis
  - 16.10.2. Component
  - 16.10.3. Deployment Mode
  - 16.10.4. Technology
  - 16.10.5. Drug Type
  - 16.10.6. Workflow
  - 16.10.7. Therapeutic Stage
  - 16.10.8. Application
  - 16.10.9. End User
- 16.11. Poland AI-based Drug Repurposing Market
  - 16.11.1. Country Segmental Analysis
  - 16.11.2. Component
  - 16.11.3. Deployment Mode
  - 16.11.4. Technology
  - 16.11.5. Drug Type
  - 16.11.6. Workflow
  - 16.11.7. Therapeutic Stage
  - 16.11.8. Application
  - 16.11.9. End User
- 16.12. Russia & CIS AI-based Drug Repurposing Market
  - 16.12.1. Country Segmental Analysis
  - 16.12.2. Component
  - 16.12.3. Deployment Mode
  - 16.12.4. Technology
  - 16.12.5. Drug Type
  - 16.12.6. Workflow
  - 16.12.7. Therapeutic Stage
  - 16.12.8. Application
  - 16.12.9. End User
- 16.13. Rest of Europe AI-based Drug Repurposing Market
  - 16.13.1. Component
  - 16.13.2. Deployment Mode
  - 16.13.3. Technology
  - 16.13.4. Drug Type
  - 16.13.5. Workflow
  - 16.13.6. Therapeutic Stage
  - 16.13.7. Application
  - 16.13.8. End User
17. Asia Pacific AI-based Drug Repurposing Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Asia Pacific AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Component
  - 17.3.2. Deployment Mode
  - 17.3.3. Technology
  - 17.3.4. Drug Type
  - 17.3.5. Workflow
  - 17.3.6. Therapeutic Stage
  - 17.3.7. Application
  - 17.3.8. End User
  - 17.3.9. Country
    - 17.3.9.1. China
    - 17.3.9.2. India
    - 17.3.9.3. Japan
    - 17.3.9.4. South Korea
    - 17.3.9.5. Australia and New Zealand
    - 17.3.9.6. Indonesia
    - 17.3.9.7. Malaysia
    - 17.3.9.8. Thailand
    - 17.3.9.9. Vietnam
    - 17.3.9.10. Rest of Asia Pacific
- 17.4. China AI-based Drug Repurposing Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Component
  - 17.4.3. Deployment Mode
  - 17.4.4. Technology
  - 17.4.5. Drug Type
  - 17.4.6. Workflow
  - 17.4.7. Therapeutic Stage
  - 17.4.8. Application
  - 17.4.9. End User
- 17.5. India AI-based Drug Repurposing Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Component
  - 17.5.3. Deployment Mode
  - 17.5.4. Technology
  - 17.5.5. Drug Type
  - 17.5.6. Workflow
  - 17.5.7. Therapeutic Stage
  - 17.5.8. Application
  - 17.5.9. End User
- 17.6. Japan AI-based Drug Repurposing Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Component
  - 17.6.3. Deployment Mode
  - 17.6.4. Technology
  - 17.6.5. Drug Type
  - 17.6.6. Workflow
  - 17.6.7. Therapeutic Stage
  - 17.6.8. Application
  - 17.6.9. End User
- 17.7. South Korea AI-based Drug Repurposing Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Component
  - 17.7.3. Deployment Mode
  - 17.7.4. Technology
  - 17.7.5. Drug Type
  - 17.7.6. Workflow
  - 17.7.7. Therapeutic Stage
  - 17.7.8. Application
  - 17.7.9. End User
- 17.8. Australia and New Zealand AI-based Drug Repurposing Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Component
  - 17.8.3. Deployment Mode
  - 17.8.4. Technology
  - 17.8.5. Drug Type
  - 17.8.6. Workflow
  - 17.8.7. Therapeutic Stage
  - 17.8.8. Application
  - 17.8.9. End User
- 17.9. Indonesia AI-based Drug Repurposing Market
  - 17.9.1. Country Segmental Analysis
  - 17.9.2. Component
  - 17.9.3. Deployment Mode
  - 17.9.4. Technology
  - 17.9.5. Drug Type
  - 17.9.6. Workflow
  - 17.9.7. Therapeutic Stage
  - 17.9.8. Application
  - 17.9.9. End User
- 17.10. Malaysia AI-based Drug Repurposing Market
  - 17.10.1. Country Segmental Analysis
  - 17.10.2. Component
  - 17.10.3. Deployment Mode
  - 17.10.4. Technology
  - 17.10.5. Drug Type
  - 17.10.6. Workflow
  - 17.10.7. Therapeutic Stage
  - 17.10.8. Application
  - 17.10.9. End User
- 17.11. Thailand AI-based Drug Repurposing Market
  - 17.11.1. Country Segmental Analysis
  - 17.11.2. Component
  - 17.11.3. Deployment Mode
  - 17.11.4. Technology
  - 17.11.5. Drug Type
  - 17.11.6. Workflow
  - 17.11.7. Therapeutic Stage
  - 17.11.8. Application
  - 17.11.9. End User
- 17.12. Vietnam AI-based Drug Repurposing Market
  - 17.12.1. Country Segmental Analysis
  - 17.12.2. Component
  - 17.12.3. Deployment Mode
  - 17.12.4. Technology
  - 17.12.5. Drug Type
  - 17.12.6. Workflow
  - 17.12.7. Therapeutic Stage
  - 17.12.8. Application
  - 17.12.9. End User
- 17.13. Rest of Asia Pacific AI-based Drug Repurposing Market
  - 17.13.1. Country Segmental Analysis
  - 17.13.2. Component
  - 17.13.3. Deployment Mode
  - 17.13.4. Technology
  - 17.13.5. Drug Type
  - 17.13.6. Workflow
  - 17.13.7. Therapeutic Stage
  - 17.13.8. Application
  - 17.13.9. End User
18. Middle East AI-based Drug Repurposing Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Middle East AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Component
  - 18.3.2. Deployment Mode
  - 18.3.3. Technology
  - 18.3.4. Drug Type
  - 18.3.5. Workflow
  - 18.3.6. Therapeutic Stage
  - 18.3.7. Application
  - 18.3.8. End User
  - 18.3.9. Country
    - 18.3.9.1. Turkey
    - 18.3.9.2. UAE
    - 18.3.9.3. Saudi Arabia
    - 18.3.9.4. Israel
    - 18.3.9.5. Rest of Middle East
- 18.4. Turkey AI-based Drug Repurposing Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Component
  - 18.4.3. Deployment Mode
  - 18.4.4. Technology
  - 18.4.5. Drug Type
  - 18.4.6. Workflow
  - 18.4.7. Therapeutic Stage
  - 18.4.8. Application
  - 18.4.9. End User
- 18.5. UAE AI-based Drug Repurposing Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Component
  - 18.5.3. Deployment Mode
  - 18.5.4. Technology
  - 18.5.5. Drug Type
  - 18.5.6. Workflow
  - 18.5.7. Therapeutic Stage
  - 18.5.8. Application
  - 18.5.9. End User
- 18.6. Saudi Arabia AI-based Drug Repurposing Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Component
  - 18.6.3. Deployment Mode
  - 18.6.4. Technology
  - 18.6.5. Drug Type
  - 18.6.6. Workflow
  - 18.6.7. Therapeutic Stage
  - 18.6.8. Application
  - 18.6.9. End User
- 18.7. Israel AI-based Drug Repurposing Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Component
  - 18.7.3. Deployment Mode
  - 18.7.4. Technology
  - 18.7.5. Drug Type
  - 18.7.6. Workflow
  - 18.7.7. Therapeutic Stage
  - 18.7.8. Application
  - 18.7.9. End User
- 18.8. Rest of Middle East AI-based Drug Repurposing Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Component
  - 18.8.3. Deployment Mode
  - 18.8.4. Technology
  - 18.8.5. Drug Type
  - 18.8.6. Workflow
  - 18.8.7. Therapeutic Stage
  - 18.8.8. Application
  - 18.8.9. End User
19. Africa AI-based Drug Repurposing Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Africa AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Component
  - 19.3.2. Deployment Mode
  - 19.3.3. Technology
  - 19.3.4. Drug Type
  - 19.3.5. Workflow
  - 19.3.6. Therapeutic Stage
  - 19.3.7. Application
  - 19.3.8. End User
  - 19.3.9. Country
    - 19.3.9.1. South Africa
    - 19.3.9.2. Egypt
    - 19.3.9.3. Nigeria
    - 19.3.9.4. Algeria
    - 19.3.9.5. Rest of Africa
- 19.4. South Africa AI-based Drug Repurposing Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Component
  - 19.4.3. Deployment Mode
  - 19.4.4. Technology
  - 19.4.5. Drug Type
  - 19.4.6. Workflow
  - 19.4.7. Therapeutic Stage
  - 19.4.8. Application
  - 19.4.9. End User
- 19.5. Egypt AI-based Drug Repurposing Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Component
  - 19.5.3. Deployment Mode
  - 19.5.4. Technology
  - 19.5.5. Drug Type
  - 19.5.6. Workflow
  - 19.5.7. Therapeutic Stage
  - 19.5.8. Application
  - 19.5.9. End User
- 19.6. Nigeria AI-based Drug Repurposing Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Component
  - 19.6.3. Deployment Mode
  - 19.6.4. Technology
  - 19.6.5. Drug Type
  - 19.6.6. Workflow
  - 19.6.7. Therapeutic Stage
  - 19.6.8. Application
  - 19.6.9. End User
- 19.7. Algeria AI-based Drug Repurposing Market
  - 19.7.1. Country Segmental Analysis
  - 19.7.2. Component
  - 19.7.3. Deployment Mode
  - 19.7.4. Technology
  - 19.7.5. Drug Type
  - 19.7.6. Workflow
  - 19.7.7. Therapeutic Stage
  - 19.7.8. Application
  - 19.7.9. End User
- 19.8. Rest of Africa AI-based Drug Repurposing Market
  - 19.8.1. Country Segmental Analysis
  - 19.8.2. Component
  - 19.8.3. Deployment Mode
  - 19.8.4. Technology
  - 19.8.5. Drug Type
  - 19.8.6. Workflow
  - 19.8.7. Therapeutic Stage
  - 19.8.8. Application
  - 19.8.9. End User
20. South America AI-based Drug Repurposing Market Analysis
- 20.1. Key Segment Analysis
- 20.2. Regional Snapshot
- 20.3. South America AI-based Drug Repurposing Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 20.3.1. Component
  - 20.3.2. Deployment Mode
  - 20.3.3. Technology
  - 20.3.4. Drug Type
  - 20.3.5. Workflow
  - 20.3.6. Therapeutic Stage
  - 20.3.7. Application
  - 20.3.8. End User
  - 20.3.9. Country
    - 20.3.9.1. Brazil
    - 20.3.9.2. Argentina
    - 20.3.9.3. Rest of South America
- 20.4. Brazil AI-based Drug Repurposing Market
  - 20.4.1. Country Segmental Analysis
  - 20.4.2. Component
  - 20.4.3. Deployment Mode
  - 20.4.4. Technology
  - 20.4.5. Drug Type
  - 20.4.6. Workflow
  - 20.4.7. Therapeutic Stage
  - 20.4.8. Application
  - 20.4.9. End User
- 20.5. Argentina AI-based Drug Repurposing Market
  - 20.5.1. Country Segmental Analysis
  - 20.5.2. Component
  - 20.5.3. Deployment Mode
  - 20.5.4. Technology
  - 20.5.5. Drug Type
  - 20.5.6. Workflow
  - 20.5.7. Therapeutic Stage
  - 20.5.8. Application
  - 20.5.9. End User
- 20.6. Rest of South America AI-based Drug Repurposing Market
  - 20.6.1. Country Segmental Analysis
  - 20.6.2. Component
  - 20.6.3. Deployment Mode
  - 20.6.4. Technology
  - 20.6.5. Drug Type
  - 20.6.6. Workflow
  - 20.6.7. Therapeutic Stage
  - 20.6.8. Application
  - 20.6.9. End User
21. Key Players/ Company Profile
- 21.1. BenevolentAI Limited
  - 21.1.1. Company Details/ Overview
  - 21.1.2. Company Financials
  - 21.1.3. Key Customers and Competitors
  - 21.1.4. Business/ Industry Portfolio
  - 21.1.5. Product Portfolio/ Specification Details
  - 21.1.6. Pricing Data
  - 21.1.7. Strategic Overview
  - 21.1.8. Recent Developments
- 21.2. BioXcel Therapeutics Inc
- 21.3. BullFrog AI Holdings, Inc.
- 21.4. Healx Limited
- 21.5. Insilico Medicine, Inc.
- 21.6. Lantern Pharma Inc.
- 21.7. Recursion Pharmaceuticals, Inc.
- 21.8. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation